Home » Stocks » VACC

Vaccitech plc (VACC)

Stock Price: $15.18 USD 0.50 (3.41%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $14.74 -0.44 (-2.90%) Jul 26, 5:38 PM
Market Cap 517.10M
Revenue (ttm) 4.82M
Net Income (ttm) n/a
Shares Out 34.06M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $15.18
Previous Close $14.68
Change ($) 0.50
Change (%) 3.41%
Day's Open 15.27
Day's Range 14.61 - 15.27
Day's Volume 10,895
52-Week Range 12.25 - 17.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...

Other stocks mentioned: ABUS
2 weeks ago - Benzinga

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...

1 month ago - GlobeNewsWire

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...

2 months ago - GlobeNewsWire

Here's how VACC stock has performed thus far following the company's highly anticipated IPO in the market today. The post VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today appeared firs...

2 months ago - InvestorPlace

OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immuno...

2 months ago - GlobeNewsWire

Biotech startup Vaccitech Plc, which owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, filed for a U.S. initial public offering on Friday.

3 months ago - Reuters

Vaccitech plc has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

Vaccitech's decision to float in the US is a blow to the UK but its success reveals some important and reassuring developments.

3 months ago - Sky News

Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public

3 months ago - The Guardian

About VACC

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. We use our proprietary platform to develop product candidates that stimulate powerful, targeted immune responses against pathogens and tumor cells. We design our product candidates to stimulate immune responses that are robust, highly specific, and are differentiated by the magnitude of the T cell populations induced, which exhibit critical f... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 2021
CEO
William Enright
Employees
49
Stock Exchange
NASDAQ
Ticker Symbol
VACC
Full Company Profile

Financial Performance

In 2020, Vaccitech's revenue was $4.82 million, a decrease of -29.58% compared to the previous year's $6.85 million. Losses were -$17.71 million, -14.59% less than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Vaccitech is 24.50, which is an increase of 61.40% from the latest price.

Price Target
$24.50
(61.40% upside)